23170-45-8

Usage

Uses

Used in Pharmaceutical Industry:
5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID METHYL ESTER is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a versatile building block in the development of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of organic chemistry, 5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID METHYL ESTER is used as a key intermediate in the preparation of triazines and their phosphorus analogs. These compounds are synthesized through various chemical reactions such as cyclization, ring transformation, aromatization, and substituent modification. The versatility of 5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID METHYL ESTER makes it valuable in the development of new chemical entities with diverse applications.
Used in Agrochemical Industry:
5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID METHYL ESTER may also find applications in the agrochemical industry as a starting material for the synthesis of various pesticides and agrochemicals. Its unique chemical properties can be exploited to develop new compounds with improved efficacy and selectivity, contributing to the development of more sustainable and environmentally friendly agricultural practices.
Used in Material Science:
The compound's potential applications extend to the field of material science, where it can be used as a component in the development of novel materials with specific properties. For example, it may be used in the synthesis of advanced polymers, coatings, or other materials with unique mechanical, thermal, or electrical properties.

InChI:InChI=1/C6H8N2O2/c1-4-5(3-7-8-4)6(9)10-2/h3H,1-2H3,(H,7,8)

Upstream product

• 67-56-1 methanol 
• 40704-11-8 3-methyl-1H-pyrazole-4-carboxylic acid 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 105-45-3 acetoacetic acid methyl ester 
• 3724-43-4 Vilsmeier reagent 
• 23326-27-4 Methyl 2-butynoate 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 145631-09-0 1-Amino-5-methylpyrazol-4-carbonsaeure-methylester 
• 150017-44-0 methyl 4-methyl-1,2,3-triazine-5-carboxylate 
• 40704-11-8 3-methyl-1H-pyrazole-4-carboxylic acid 
• 1252590-73-0 methyl 1-(2-bromobenzyl)-3-methyl-1H-pyrazole-4-carboxylate 
• 288252-42-6 1-benzyl-5-methyl-1H-pyrazole-4-carboxylic acid 
• 1450651-28-1 1-benzyl-N-((2-hydroxy-4,6-dimethylpyridin-3-yl)methyl)-5-methyl-1H-pyrazole-4-carboxamide 
• 1450651-30-5 N-((2-hydroxy-4,6-dimethylpyridin-3-yl)methyl)-5-methyl-1-phenethyl-1H-pyrazole-4-carboxamide 
• 80326-70-1 methyl 5-methyl-1-(phenylmethyl)-1H-pyrazole-4-carboxylate 
• 1450657-86-9 methyl 5-methyl-1-phenethyl-1H-pyrazole-4-carboxylate 
• 1450657-72-3 methyl 3-methyl-1-(1-phenylethyl)-1H-pyrazole-4-carboxylate 
• 1450657-74-5 methyl 5-methyl-1-(1-phenylethyl)-1H-pyrazole-4-carboxylate 
• 1450657-76-7 3-methyl-1-(1-phenylethyl)-1H-pyrazole-4-carboxylic acid 

Relevant academic research and scientific papers

COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS

Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 antagonist, ASKl inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, diacyl glycerol acyltransferase-1 inhibitor, sodium -bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or GLP-1 agonist, or a combination thereof.

FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE

Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

Discovery, design, and synthesis of indole-based EZH2 inhibitors

The discovery and optimization of a series of small molecule EZH2 inhibitors is described. Starting from dimethylpyridone HTS hit (2), a series of indole-based EZH2 inhibitors were identified. Biochemical potency and microsomal stability were optimized during these studies and afforded compound 22. This compound demonstrates nanomolar levels of biochemical potency (IC50 = 0.002 μM), cellular potency (EC50 = 0.080 μM), and afforded tumor regression when dosed (200 mpk SC BID) in an EZH2 dependent tumor xenograft model.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

Direct synthesis of pyrazolo[5,1-a]isoindoles via intramolecular palladium-catalyzed C-H bond activation

An efficient, direct synthesis of pyrazolo-[5,1-a]isoindoles employing a palladium-catalyzed intramolecular C-H bond activation of 1-(2-halobenzyl) pyrazoles has been developed. The use of lithium chloride (LiCl) was found to be essential in these reactions, to suppress further C-H bond activation at the C-3 position of pyrazolo[5,1-a]isoindole, when C-3 is unsubstituted. This protocol can be applied to the synthesis of a pyrazolo[5,1-a]isoquinoline possessing a six-membered central ring system and a fully substituted pyrazolo[5,1-a]isoindole using sequential intra- and intermolecular C-H bond activation.

INHIBITORS OF CHECKPOINT KINASES

The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound

1,3-Dipolar Cycloaddition Reactions of Transition-Metal Carbene Complexes and the Formal Pyridinannulation of the Cycloadducts

The first examples of 1,3-dipolar cycloadditions of α,β-unsaturated carbene complexes are described.The reaction of alkynylcarbene complexes with diazomethane gives a mixture of two products.The first arises from a cycloaddition on the carbon-carbon